Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Study identifier:D133HR00022

ClinicalTrials.gov identifier:NCT05958134

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL: Multicenter Retrospective Study (Real World Evidence – RWE)

Medical condition

Diffuse Large B Cell Lymphoma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

400

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 15 Jul 2023
Estimated Primary Completion Date: 10 May 2024
Estimated Study Completion Date: 10 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Hospital Israelita Albert Einstein

Inclusion and exclusion criteria